Clinical and serologic characteristics of patients at enrollment
| . | All patients (n = 23) . | WAIHA patients (n = 14) . | CHD patients (n = 9) . |
|---|---|---|---|
| Male, n (%) | 7 (30.4%) | 6 (43%) | 1 (11%) |
| Female, n (%) | 16 (69.6%) | 8 (57%) | 8 (89%) |
| Median age, y (range) | 56 (27-75) | 46.5 (27-75) | 61 (30-71) |
| Newly diagnosed patients, n (%) | 7 (30.4%) | 6 (43%) | 1 (11%) |
| Relapsed after steroid treatment, n (%) | 16 (69.6%) | 8 (57%) | 8 (89%) |
| Median interval from diagnosis to rituximab, mo (range) | 23 (0-276) | 8 (0-122) | 46 (7-276) |
| . | All patients (n = 23) . | WAIHA patients (n = 14) . | CHD patients (n = 9) . |
|---|---|---|---|
| Male, n (%) | 7 (30.4%) | 6 (43%) | 1 (11%) |
| Female, n (%) | 16 (69.6%) | 8 (57%) | 8 (89%) |
| Median age, y (range) | 56 (27-75) | 46.5 (27-75) | 61 (30-71) |
| Newly diagnosed patients, n (%) | 7 (30.4%) | 6 (43%) | 1 (11%) |
| Relapsed after steroid treatment, n (%) | 16 (69.6%) | 8 (57%) | 8 (89%) |
| Median interval from diagnosis to rituximab, mo (range) | 23 (0-276) | 8 (0-122) | 46 (7-276) |